CI=confidence interval; DTaP=diphtheria, tetanus, and acellular pertussis; WHO=World Health Organization.
*WHO-defined typical pertussis is ≥21 days of paroxysmal cough with infection confirmed by culture and/or serologic testing.2
†Clinically milder disease is infection confirmed by culture and/or serologic testing with >7 or ≥14 days of any cough.2
‡The mean length of follow-up was 17 months, beginning 30 days after the third dose of vaccine.2
In an extended, unblinded follow-up period among children 3 to 6 years, the efficacy of INFANRIX against WHO-defined pertussis was 86% (95% CI: 79-91). Thus, efficacy against pertussis in children administered 3 doses of INFANRIX in infancy was sustained to 6 years of age.1,2
PEDIARIX is approved for use as a 3-dose primary series and by itself does not constitute a complete vaccination course for DTaP.1